NCT02097849

A Phase 3b Study of BG00012's Effect on Vaccination Response in Subjects With Relapsed Forms of Multiple Sclerosis

A Randomized, Open-Label Study to Assess the Effects of BG00012 on the Immune Response to Vaccination and on Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis

Conditions: Mulitple Sclerosis
Sponsor: Biogen Idec
Phase  III

NCT02079480

Study to Evaluate the Safety, Tolerability, PK, and PD of CD40 in Healthy Subjects (CD40 FIH)

Condition: n/a  (Healthy Adults)
Sponsor: Bristol-Myers Squibb
Phase I

NCT01911234

Clinical Efficacy of TNF-Kinoid in Patients With Rheumatoid Arthritis 

Condition: Rheumatoid Arthritis
Sponsor: NeoVacs
Phase: II 

NCT01910662

Characterisation of T-cell Response to Keyhole Limpet Hemocyanin (KLH) and Tuberculin Pruified Protein Derivative (PPD)

Condition: Dermatitis 
Sponsor: GlaxoSmithKline
Phase: 1

NCT01644968

Phase 1 Study of Anti-OX40 in Patients With Advanced Cancer

Conditions: Advanced Cancer
Sponsors: Providence Health & Services
Phase: I 

Relates to article in Cancer Research

Characterization of human peripheral and intestinal T-cell responses after mucosal antigen exposure: induction of tolerance vs. immunization by oral administration of KLH

Condition: n/a (Healthy Volunteers)
Sponsor: Charite University Berlin
Phase: n/a 

NCT01552681

Baminercept in Sjögren's Syndrome

Conditions: Sjögren's Syndrome
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID)
Phase: II

NCT01489956

A Study to Determine the Immunogenicity and Oral Tolerance to Keyhole Limpet Hemocyanin (KLH)

Conditions: Autoimmune Disorders
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID) 
Phase 0 completed

mRNA-transfected Dendritic Cell Vaccination in High Risk Uveal Melanoma Patients

Conditions: Uveal Melanoma 
Sponsors: Radboud University Nijmegen Medical Centre
Phase n/a

NCT00774943

A Study of AMG 557 in Adults With Systemic Lupus Erythematosus

Conditions: Systemic Lupus Erythematosus
Sponsors: Amgen
Phase I